Lake Street Advisors Group LLC Lowers Holdings in IQVIA Holdings Inc. (NYSE:IQV)

Lake Street Advisors Group LLC reduced its position in IQVIA Holdings Inc. (NYSE:IQV) by 3.0% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,011 shares of the medical research company’s stock after selling 63 shares during the period. Lake Street Advisors Group LLC’s holdings in IQVIA were worth $395,000 at the end of the most recent quarter.

Other large investors have also recently made changes to their positions in the company. Capital Performance Advisors LLP purchased a new stake in IQVIA in the 3rd quarter worth about $27,000. Synergy Asset Management LLC purchased a new position in shares of IQVIA in the 4th quarter valued at $33,000. Avior Wealth Management LLC raised its position in shares of IQVIA by 117.6% in the 3rd quarter. Avior Wealth Management LLC now owns 161 shares of the medical research company’s stock worth $38,000 after acquiring an additional 87 shares in the last quarter. Assetmark Inc. boosted its position in IQVIA by 612.5% during the third quarter. Assetmark Inc. now owns 228 shares of the medical research company’s stock valued at $54,000 after purchasing an additional 196 shares in the last quarter. Finally, Ashton Thomas Securities LLC purchased a new position in IQVIA in the third quarter valued at about $57,000. 89.62% of the stock is currently owned by institutional investors.

Insider Activity at IQVIA

In other IQVIA news, Director John G. Danhakl acquired 1,275 shares of the firm’s stock in a transaction on Tuesday, December 3rd. The stock was purchased at an average cost of $200.58 per share, for a total transaction of $255,739.50. Following the transaction, the director now owns 1,275 shares of the company’s stock, valued at $255,739.50. The trade was a ∞ increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 1.60% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

IQV has been the subject of a number of research analyst reports. StockNews.com lowered IQVIA from a “buy” rating to a “hold” rating in a research note on Thursday, November 28th. TD Cowen cut their target price on shares of IQVIA from $270.00 to $255.00 and set a “buy” rating for the company in a report on Friday, November 1st. Stifel Nicolaus lowered their price target on shares of IQVIA from $273.00 to $261.00 and set a “buy” rating on the stock in a report on Friday, February 7th. JPMorgan Chase & Co. decreased their price objective on shares of IQVIA from $240.00 to $232.00 and set an “overweight” rating on the stock in a report on Tuesday, February 18th. Finally, Royal Bank of Canada reissued an “outperform” rating and issued a $270.00 price objective on shares of IQVIA in a research note on Monday, February 10th. Four research analysts have rated the stock with a hold rating, sixteen have issued a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $251.22.

IQVIA Price Performance

Shares of IQV opened at $186.40 on Friday. The firm has a market capitalization of $32.82 billion, a price-to-earnings ratio of 24.85, a price-to-earnings-growth ratio of 1.99 and a beta of 1.48. The company has a debt-to-equity ratio of 2.12, a quick ratio of 0.84 and a current ratio of 0.84. The stock’s fifty day moving average is $199.30 and its 200-day moving average is $215.26. IQVIA Holdings Inc. has a one year low of $184.66 and a one year high of $261.73.

IQVIA (NYSE:IQV) last released its earnings results on Thursday, February 6th. The medical research company reported $2.90 EPS for the quarter, missing analysts’ consensus estimates of $3.11 by ($0.21). IQVIA had a return on equity of 28.81% and a net margin of 8.91%. Equities analysts anticipate that IQVIA Holdings Inc. will post 10.84 EPS for the current year.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.